Ann: 1H FY22 Results - Webcast Recording, page-86

The portfolio of products potentially derivable just from the NovoSorb polymer family could eventually earn multiples of Integra’s sales simply due to its versatility. Hernia repair, plastic surgery/breast reconstruction, and dermal depots are current product candidates, but other applications once thought promising may well prove so again, including resorbable stents, bone fixation devices and cements, and bone scaffolds. There are very likely many more applications that will evolve over time as more and more surgeons become familiar with the product range. It also should be possible for the company to self fund the research and trials required to bring products to market without reliance on inconstant partners. That’s the nice thing about having a company underpinned by a hugely successful cash generating machine. Diversity won’t be an issue.

And that’s without considering any M&A activity.